Aditum Bio

Tempero Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment and prevention of substance use disorders. The company aims to address the challenges faced by individuals struggling with addiction, providing transformative solutions that help patients overcome treatment obstacles and support their recovery journey. Through its specialized approach, Tempero Bio is dedicated to improving the lives of those affected by substance use disorders and related conditions.

Hubpay is an independently regulated provider of cross-border money services that aims to enhance financial inclusion in emerging markets. The company operates an online financial platform designed to facilitate overseas money transfers, offering a range of services including market-leading foreign exchange, multi-currency accounts, collections, and payment systems. By leveraging data science, Hubpay delivers accessible and affordable financial solutions to users regardless of their income level, enabling them to conduct instant money transfers with ease. This approach allows businesses to concentrate on growth while benefiting from reliable and responsible financial services.

Via Nova Therapeutics is to discover and develop therapeutics for acute and subacute viral infections for which current treatments are lacking or inadequate. The current programs were part of an antiviral portfolio led by the founders while at Novartis and target several important respiratory viruses (including influenza viruses, adenoviruses, and rhinoviruses) as well as human polyomaviruses, which produce severe disease in immunocompromised hosts. The company targets fundamental mechanisms of viral replication and accordingly can support discovery of novel therapeutics for other viral infections as well.

Versanis Bio is focused on discovering and developing medicines that target medical conditions commonly found in older adults. The company is advancing Bimagrumab, a human monoclonal antibody that inhibits activin type II receptors, blocking the action of ligands such as activin A and myostatin. Previous studies conducted by Novartis involved over 1,500 participants and demonstrated that Bimagrumab consistently induced significant fat loss while preserving lean mass. Additionally, the treatment has shown improvements in HbA1c levels and other cardiometabolic parameters, offering a promising option for overweight and obese adults aiming to achieve and maintain a healthier body composition.

Anteris Bio is developing a new therapy for the treatment of renal disease.